Galderma Group AG
🇨🇭Switzerland
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 100
- Registration Number
- NCT01887808
Patch Test Skin Irritation/Sensitization of Cetaphil Daily Advance Ultra Hydration Lotion
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 100
- Registration Number
- NCT01885130
Patient-Reported Outcome Of Facial Erythema (PROOF)
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 92
- Registration Number
- NCT01885000
- Locations
- 🇩🇪
Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany
🇩🇪Universitätsklinikum Düsseldorf, Düsseldorf, Germany
🇩🇪Universitätsklinikum Münster, Klinik für Hautkrankheiten, Münster, Germany
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2013-06-20
- Last Posted Date
- 2014-11-06
- Lead Sponsor
- Galderma R&D
- Registration Number
- NCT01882712
Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-06-18
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 503
- Registration Number
- NCT01880320
- Locations
- 🇨🇦
Galderma Investigational Site, Waterloo, Canada
🇨🇦Galderma Investigational site, Surrey, Canada
🇺🇸Galderma Investigationnal Site, Mobile, Alabama, United States
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 24
- Registration Number
- NCT01872715
- Locations
- 🇺🇸
Stephens & Associates Dallas Research Center, Carrollton, Texas, United States
Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses
- First Posted Date
- 2013-04-01
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 131
- Registration Number
- NCT01821391
- Locations
- 🇸🇪
Investigational site, Norrköping, Sweden
🇪🇸Investigative site, Pamplona, Spain
An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 12
- Registration Number
- NCT01807455
- Locations
- 🇧🇪
Skin and Laser Center, Boom, Belgium
Durolane Compared to Saline in Patients With Unilateral Knee Osteoarthritis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 218
- Registration Number
- NCT01806207
- Locations
- 🇬🇧
Southampton General Hospital, Southhampton, Hampshire, United Kingdom
A Non-interventional Study to Evaluate the Use of Pliaglis in Daily Practice
Completed
- Conditions
- First Posted Date
- 2013-02-27
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 582
- Registration Number
- NCT01800474
- Locations
- 🇫🇷
Centre Médical Saint-Jean, Arras, France
🇪🇸Clínica Dermatológica Dr. Guillén, Valencia, Spain
🇬🇧Swansea Laser Clinic, Swansea, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath